NeuroMetrix, Inc. (NURO)
NASDAQ: NURO · IEX Real-Time Price · USD
4.440
+0.070 (1.60%)
At close: May 1, 2024, 4:00 PM
4.700
+0.260 (5.86%)
After-hours: May 1, 2024, 5:00 PM EDT
NeuroMetrix Revenue
In the year 2023, NeuroMetrix had annual revenue of $5.90M, a decrease of -28.52%. Revenue in the quarter ending December 31, 2023 was $1.32M, a -28.67% decrease year-over-year.
Revenue (ttm)
$5.90M
Revenue Growth
-28.52%
P/S Ratio
1.49
Revenue / Employee
$226,978
Employees
26
Market Cap
8.82M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5.90M | -2.35M | -28.52% |
Dec 31, 2022 | 8.26M | 2.58K | 0.03% |
Dec 31, 2021 | 8.25M | 875.52K | 11.87% |
Dec 31, 2020 | 7.38M | -1.89M | -20.43% |
Dec 31, 2019 | 9.27M | -6.82M | -42.37% |
Dec 31, 2018 | 16.09M | -1.00M | -5.86% |
Dec 31, 2017 | 17.09M | 5.06M | 42.11% |
Dec 31, 2016 | 12.03M | 4.73M | 64.76% |
Dec 31, 2015 | 7.30M | 1.79M | 32.42% |
Dec 31, 2014 | 5.51M | 233.96K | 4.43% |
Dec 31, 2013 | 5.28M | -2.30M | -30.32% |
Dec 31, 2012 | 7.58M | -2.82M | -27.14% |
Dec 31, 2011 | 10.40M | -3.50M | -25.20% |
Dec 31, 2010 | 13.90M | -12.24M | -46.82% |
Dec 31, 2009 | 26.14M | -4.98M | -16.01% |
Dec 31, 2008 | 31.12M | -12.55M | -28.73% |
Dec 31, 2007 | 43.67M | -11.58M | -20.96% |
Dec 31, 2006 | 55.25M | 20.95M | 61.09% |
Dec 31, 2005 | 34.30M | 16.38M | 91.39% |
Dec 31, 2004 | 17.92M | 8.75M | 95.47% |
Dec 31, 2003 | 9.17M | 4.94M | 116.98% |
Dec 31, 2002 | 4.23M | 760.63K | 21.96% |
Dec 31, 2001 | 3.46M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Molecular Templates | 57.31M |
TRxADE HEALTH | 8.27M |
Aeterna Zentaris | 4.50M |
Notable Labs | 310.00K |
Kazia Therapeutics | 15.65K |
NURO News
- 12 days ago - NeuroMetrix Announces Steps Taken to Enhance Shareholder Value - GlobeNewsWire
- 6 weeks ago - NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy - GlobeNewsWire
- 7 weeks ago - NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia - GlobeNewsWire
- 7 weeks ago - Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired - Accesswire
- 2 months ago - Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc. - Accesswire
- 2 months ago - NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights - GlobeNewsWire
- 2 months ago - NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call - GlobeNewsWire
- 2 months ago - NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value - GlobeNewsWire